Research programme: natural killer cells based therapeutics - Mendus
Latest Information Update: 29 Jun 2023
At a glance
- Originator Mendus
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 May 2023 Reseaerch programme: natural killer cells-based therapeutics - Mendus is available for licensing as of 21 May 2023. https://immunicum-uploads-prod.s3.amazonaws.com/uploads/2023/04/Mendus_AnnualReport_2022_04_17b.pdf
- 11 Nov 2022 Preclinical trials in Cancer in Sweden (Parenteral) (before November 2022)
- 11 Nov 2022 Pharmadynamics data from preclinical studies presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC-2022)